Immunotherapy management in special cancer patient populations

BH Ramnaraign, JA Chatzkel, ZA Al-Mansour… - JCO Oncology …, 2021 - ascopubs.org
Patients with autoimmune disorders, multiple comorbidities, poor performance status,
advanced age, and infection with SARS-CoV-2 (COVID-19) each represent unique …
被引用次数：12 相关文章

Immunotherapy Management in Special Cancer Patient Populations

BH Ramnaraign, JA Chatzkel… - JCO oncology …, 2021 - pubmed.ncbi.nlm.nih.gov
Patients with autoimmune disorders, multiple comorbidities, poor performance status,
advanced age, and infection with SARS-CoV-2 (COVID-19) each represent unique …

Immunotherapy Management in Special Cancer Patient Populations

BH Ramnaraign, JA Chatzkel… - JCO: Oncology …, 2021 - ingentaconnect.com
Patients with autoimmune disorders, multiple comorbidities, poor performance status,
advanced age, and infection with SARS-CoV-2 (COVID-19) each represent unique …

Immunotherapy Management in Special Cancer Patient Populations.

BH Ramnaraign, JA Chatzkel, ZA Al-Mansour… - JCO Oncology …, 2021 - europepmc.org
Patients with autoimmune disorders, multiple comorbidities, poor performance status,
advanced age, and infection with SARS-CoV-2 (COVID-19) each represent unique …